Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Rich

Showing results (361-370 of 558) with videos related to

Pageof 56
Sort By:
Cancer Research|December 24, 2009
Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasivenessSrinivasulu Chigurupati, Rajarajeswari Venkataraman, Daniel Barrera, et al.
Nucleic Acids Research|June 28, 2021
Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylaseZhen Xia, Min Tang, Jiayan Ma, et al.
Cell Death and Differentiation|October 15, 2016
Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cellsYu Shi, Wenchao Zhou, Lin Cheng, et al.
Cell Reports|June 2, 2026
NAT10-dependent N<sup>4</sup>-acetylcytidine reprograms R-loops and promotes cancer stem cell growthXujia Wu, Donghai Wang, Suchet Taori, et al.
Journal of Neuro-Oncology|September 21, 2010
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyDavid A Reardon, Annick Desjardins, Katherine Peters, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I TrialsPriscilla Chan, Yoshiko Nagai, Qiulian Wu, et al.
Neuro-Oncology|April 1, 2025
Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I TrialsPriscilla Chan, Yoshiko Nagai, Qiulian Wu, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2021
Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastomaNajla Kfoury, Zongtai Qi, Briana C Prager, et al.
Cancer Letters|March 9, 2026
Dual role of LY96 in shaping the mesenchymal glioblastoma ecosystem through stem cell maintenance and macrophage MES-like reprogrammingDanyang Shan, Chenfei Lu, Hang Yu, et al.
Neuro-Oncology|December 15, 2022
Novel INHAT repressor drives glioblastoma growth by promoting ribosomal DNA transcription in glioma stem cellsWeiwei Tao, Hong Lei, Wenlong Luo, et al.
Pageof 56

Showing results (361-370 of 558) with videos related to

Sort By:
Pageof 56
Cancer Research|December 24, 2009
Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasivenessSrinivasulu Chigurupati, Rajarajeswari Venkataraman, Daniel Barrera, et al.
Nucleic Acids Research|June 28, 2021
Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylaseZhen Xia, Min Tang, Jiayan Ma, et al.
Cell Death and Differentiation|October 15, 2016
Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cellsYu Shi, Wenchao Zhou, Lin Cheng, et al.
Cell Reports|June 2, 2026
NAT10-dependent N<sup>4</sup>-acetylcytidine reprograms R-loops and promotes cancer stem cell growthXujia Wu, Donghai Wang, Suchet Taori, et al.
Journal of Neuro-Oncology|September 21, 2010
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapyDavid A Reardon, Annick Desjardins, Katherine Peters, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I TrialsPriscilla Chan, Yoshiko Nagai, Qiulian Wu, et al.
Neuro-Oncology|April 1, 2025
Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I TrialsPriscilla Chan, Yoshiko Nagai, Qiulian Wu, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 14, 2021
Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastomaNajla Kfoury, Zongtai Qi, Briana C Prager, et al.
Cancer Letters|March 9, 2026
Dual role of LY96 in shaping the mesenchymal glioblastoma ecosystem through stem cell maintenance and macrophage MES-like reprogrammingDanyang Shan, Chenfei Lu, Hang Yu, et al.
Neuro-Oncology|December 15, 2022
Novel INHAT repressor drives glioblastoma growth by promoting ribosomal DNA transcription in glioma stem cellsWeiwei Tao, Hong Lei, Wenlong Luo, et al.
Pageof 56